Clinical-biological characteristics and treatment outcomes of pediatric pro-B ALL patients enrolled in BCH-2003 and CCLG-2008 protocol: a study of 121 Chinese children

Table 4 Prognostic indicators of pro-B-ALL

Clinico-biological features	Event-free survival		Multivariate analysis
Clinico-biological features	Survival rate (%)	P	HR [95% CI]	P
Age (years)
< 1	54.5 ± 15.0	0.042	–	0.534
≥ 10	87.0 ± 7.0
1–10	74.5 ± 5.0
CD20
Positive	42.9 ± 18.7	0.034	–	0.087
Negative	78.9 ± 4.2	0.034	–	0.087
KMT2A-rearranged
Positive	56.9 ± 9.1	0.013	4.142 [1.535, 11.715]	0.005
Negative	81.8 ± 4.3	0.013	Reference	0.005
MRD at day 33
≥ 1%	34.9 ± 13.2	< 0.001	–	0.376
0.01–1%	82.8 ± 5.7
< 0.01%	84.6 ± 7.1
MRD at day 78
≥ 0.1%	36.9 ± 13.8	< 0.001	9.424 [3.210, 27.662]	< 0.001
< 0.1%	85.0 ± 4.2	< 0.001	Reference	< 0.001

ISSN: 1475-2867